Envision Pharma Group’s Post

Navigating the evolving landscape of pharmaceutical innovation requires strategic adaptation, especially as the Inflation Reduction Act goes into effect in the USA and other regulatory agencies place greater emphasis on a drug's therapeutic value to patients. Recent research reveals that, despite potential revenue reductions from Medicare price negotiations, the industry can maintain the current level of drug approvals—provided we approach harnessing cost value strategically. https://lnkd.in/eWwU-sPY

With the cost of bringing therapeutics to market doubling in recent years, and the introduction of high cost cell and gene therapies to the market, the pharmaceutical and healthcare industries have been forced to develop innovative solutions to strike a balance between costs and value to patients. In our article, Paul Archer, Daniel Cummings, and I discuss new strategies in mitigating costs, maximizing ROI, and building a sustainable, patient-focused future in life sciences. 👇🏻Click below to learn more!👇🏻

Envision can help you maximize cost-value for your product through our 4P approach.

Digital transformation and data integration are two of the biggest barriers preventing life science organisations from succeeding in their R&D efforts. You have large amounts of data from clinical trials, R&D, real-world evidence, and electronic health records, yet, data silos and legacy systems often prevent you from utilizing this data. How can we support? Technology Strategy and Integration: Developing tailored digital health strategies that align with wider business goals to add value both to patients and investors. Interoperability Solutions: Breaking down data silos and implementing frameworks that ensure smooth data flow across systems, critical for delivering precision medicine and improving R&D efficiency. AI & Data Analytics: Implementing AI-driven models for drug discovery, clinical trial optimization, and personalized medicine strategies, empowering companies to predict trends and make data-backed decisions faster. Connect with me and lets talk about digital health: craig.townsend@42t.com #LifeSciences #DigitalTransformation #DataIntegration #Consulting #Innovation

Among the many takeaways from 2024, perhaps the most intriguing is the Generative AI boom, with healthcare organizations leveraging it for personalized care plans, drug discovery, and predictive analytics. It makes me more excited for the year ahead to know that Clarify Health Solutions is investing in these capabilities. How so? Check out ClaraIQ! https://lnkd.in/gm2sSFnw

📢 Exciting Case Study Announcement Join us for an insightful case study: Navigating System Complexity to Turn Data and Digital Health Concepts into Value-Adding Solutions. In this session, Ismael Gauci, Personalised Healthcare Strategy & Business Enablement Leader (formerly of Roche), will dive deep into how AI product portfolios can be positioned for success through continuous and systematic evaluation of value, maturity, and risk. 🔑 Key Highlights: • Optimising data and digital solution portfolios to create and capture value across the patient journey • Informing where to play and how to win in a fast-changing market, addressing business realities and evolving patient needs Don’t miss this opportunity to learn how to unlock the potential of AI in healthcare and drive impactful change. #PharmaAISummit #AIinHealthcare #DigitalHealth #AIProductPortfolios #HealthcareInnovation #BusinessStrategy #PatientCentricCare #GlobalBSG

💭 Still reflecting on my time at the EPA congress last week. It was such a great opportunity to engage with peers and learn more about key topics in market access. One of the talks that still lingers in my mind was a panel discussion titled ‘Ways that AI can transform Market Access’. It was a chaired by Sandro Cesaro of AstraZeneca, and involved discussions from Chris Mancill (BMS), Rogerio Ribeiro (Takeda), Saira A. Jan (Blue Cross Blue Shield of New Jersey), and Alexander Bastian (A.M. Pharma and Memo Therapeutics). It was a fascinating discussion and here are my key takeaways:   ⌛ Efficiency: AI offers vast potential to enhance efficiencies across the board. From streamlining HR processes to optimising statistical review, its applications are limitless.   💪 Real World Data Power: The power of real-world data cannot be underestimated. Leveraging the capabilities of AI and the might of RWE can create outputs – such as side effect mapping and adherence insights – which can be used to inform payer decision-making processes, leading to more informed and effective strategies.   🤝 Collaboration is key: Successful AI integration necessitates collaboration both within and across businesses. To ensure acceptability, collaboration between manufacturers and payers on what is deemed the acceptable use of AI is vital to ensuring patient access.   ❗ Risk Awareness: While AI promises great rewards, it's essential to remain mindful of associated risks. From data handling to bias mitigation, transparency is key. Leaving EPA with much food for thought and looking forward to seeing how we might integrate these insights into our work at LCP. I feel excited at the progress I have already seen in AI and am looking forward to seeing how it might be leveraged to revolutionise our approach to market access, foster collaboration, drive efficiencies, and ultimately improve patient outcomes #EPAconf #marketaccess #AI

Attention Top 50 Biopharma Companies: Consider the progress we can achieve together. Patient care and industry service should be our noble goals, with ROI naturally following. Generative Artificial Intelligence in biopharma is no longer a distant dream. It has moved beyond proof of concept (POC) and is now in production. We are at the forefront, offering multiple Gen-AI tools and solutions. These come with compliance, regulatory oversight, and a proven track record in both alpha and beta stages, far beyond POC, with measurable outputs. With all due respect: “Your red tape and lack of knowledge don’t mean the industry is static.” Advanced AI-powered tools and solutions are revolutionizing clinical development, medical affairs, and regulatory platforms, from real-world evidence (RWE) and real-world data (RWD) to biomarker analytics. Need more answers? Connect with me. I will guide you through the process.

How do you know if your medical or commercial strategy is working? We've identified four stages in the journey of insights implementation—each step higher means more value from your data. Where does your organization stand? 🤔 In our latest white paper, we explore: ➡️ How to assess your current position ➡️ Strategies for overcoming data & tech challenges ➡️ How to unlock the full potential of insights Learn more: https://hubs.la/Q02_ZvgD0 #AI #Pharma #Innovation #MedicalAffairs

2024 has witnessed an explosion of data in healthcare, bringing both immense opportunities and complex challenges. As pharma companies navigate this new landscape, human emotional intelligence remains crucial to ensure technology truly serves patients. The industry needs to leverage data and AI with a human lens, ensuring these tools address real patient needs through empathetic collaboration, transparent communication, and value-based strategies. We believe in shaping a future where data and technology drive meaningful progress in healthcare. Learn more about our approach to navigating the complexities of the healthcare landscape: https://loom.ly/QO4DtdU #HealthcareInnovation #Pharma #BioscriptGroup